Benchling is a cloud-based software platform for biology researchers and R&D organizations. It makes life science research faster and more collaborative.
Biotechnology has the potential to solve humanity’s most pressing challenges, such as disease, renewable energy, clean water, and hunger.
Benchling was founded in 2012 by Sajith Wickramasekara, Ashu Singhal and Cory Li. The company is headquartered in San Francisco, California.
Benchling offers a modern approach to note-taking. Its collaboration features; integration with Benchling's Bioregistry and Sample Tracking, Molecular Biology Suite, and Workflow Tools; rich search functions; and intuitive user interface encourage usage, so scientists can focus on the science.
Benchling is used by hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering, who depend on its suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions.
Benchling’s cloud technology has been the backbone of the biotech industry’s boom and used by more than 300,000 scientists and 1,000 R&D organizations around the globe – spanning industries like medicine, food, agriculture, materials, consumer packaged goods and energy.
Benchling is backed by Sequoia Capital, Alkeon Capital, Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital and others. The company raised $200M in Series E round on Apr 14, 2021. This brings Benchling's total funding to $311.9M to date. The latest round valued Benchling at $4B post-money.